SEC Comment Letter 0000000000-23-004693 to ALPINE IMMUNE SCIENCES, INC. (CIK 0001626199)
ALPINE IMMUNE SCIENCES, INC. (CIK 0001626199)
Date: May 5, 2023 · CIK: 0001626199 · Accession: 0000000000-23-004693
AI Filing Summary & Sentiment
File numbers found in text: 333-271517
Letter
United States securities and exchange commission logo May 5, 2023 Dr. Mitchell Gold Chief Executive Officer ALPINE IMMUNE SCIENCES, INC. 188 East Blaine Street, Suite 200 Seattle, WA 98102 Re:ALPINE IMMUNE SCIENCES, INC. Registration Statement on Form S-3 Filed April 28, 2023 File No. 333-271517 Dear Dr. Mitchell Gold: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Bryan D. King, Esq.
Show Raw Text
United States securities and exchange commission logo
May 5, 2023
Dr. Mitchell Gold
Chief Executive Officer
ALPINE IMMUNE SCIENCES, INC.
188 East Blaine Street, Suite 200
Seattle, WA 98102
Re:ALPINE IMMUNE SCIENCES, INC.
Registration Statement on Form S-3
Filed April 28, 2023
File No. 333-271517
Dear Dr. Mitchell Gold:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Bryan D. King, Esq.